

**REPORT AND ACCOUNTS  
FOR THE YEAR ENDED 30<sup>TH</sup> JUNE, 1999  
OF  
ORION INFUSION LIMITED**

কামরুল আহসান চৌধুরী এন্ড কোঃ  
**QUAMRUL AHSAN CHOWDHURY & CO.**  
*CHARTERED ACCOUNTANTS*  
Arup Bhaban, Annex Block (1st Floor)  
107, Agrabad Commercial Area  
Chittagong-4100, Bangladesh.  
Phone : 880-31-713579

**ORION INFUSION LIMITED**

**REPORT AND ACCOUNTS  
FOR THE YEAR ENDED 30<sup>TH</sup> JUNE, 1999**

AUDITORS' REPORT  
TO  
THE SHAREHOLDERS OF  
ORION INFUSION LIMITED

We have audited the accompanying Balance Sheet of Orion Infusion Limited as of 30 June 1999 and the related Profit and Loss Account and the Cash Flows Statement for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

**Basis of Opinion:**

We conducted our audit in accordance with the International Standards on Auditing as adopted by the Institute of Chartered Accountants of Bangladesh. We however could not physically verify stocks, spares, fixed assets and cash on hand at balance sheet date as our appointment was post-dated. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. The audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

**Opinion:**

In our opinion, the financial statements prepared in accordance with the International Accounting Standards as adopted by the Institute of Chartered Accountants of Bangladesh, give, subject to the contents of Schedules -3,11 and 16, a true and fair view of the Company's affairs as of 30 June 1999 and of the results of its operations and its cash flows for the year then ended and comply with the Companies Act, 1994; the Securities and Exchange Rules, 1987 and other applicable laws and regulations.

**We also report that-**

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of those books;
- c) the Company's Balance Sheet and Profit and Loss Account dealt with by the report are in agreement with the books of account; and
- d) The expenditure incurred was for the purpose of the Company's business.

Quamrul Ahsan Chowdhury & Co  
Chartered Accountants

Dated: Chittagong, 10 February, 2000

*U.A. Chowdhury*  
Q.A. Chowdhury FCA  
Proprietor



# ORION INFUSION LIMITED

## BALANCE SHEET AS AT 30 JUNE 1999

SL.NO.	PARTICULARS	SCHEDULE	1999 TAKA	1998 TAKA
1.	<u>Sources of Fund</u>			
1.1	<u>Shareholders' Fund</u>			
	a) Share Capital	3	20,35,97,600	20,35,97,600
	b) Reserves and Surplus	4	41,56,589	41,56,589
			=====	=====
			20,77,54,189	20,77,54,189
			=====	=====
2.	<u>Applications of Fund</u>			
2.1	<u>Fixed Assets</u>			
	a) Gross Block	5	24,76,92,038	24,73,24,853
	b) Less : Accumulated Depreciation		5,83,30,976	4,73,99,184
	c) Net Block		18,93,61,062	19,99,25,669
2.2	<u>Investments</u>	6	14,24,22,196	16,75,68,067
			33,17,83,258	36,74,93,736
2.3	<u>Current Assets, Loans and Advances</u>			
	a) Inventories	7	7,56,69,571	7,20,19,275
	b) Sundry Debtors	8	1,40,41,979	1,15,39,116
	c) Deposits and other Receivables	9	3,09,02,943	2,76,08,713
	d) Cash and Bank Balances	10	5,76,251	6,98,425
			12,11,90,744	11,18,65,529
	<u>Less : Current Liabilities and Provisions</u>			
	a) Bank Loans - Secured	11	36,71,30,565	34,32,29,494
	b) Liabilities for Goods Supplied	12	52,50,228	47,18,019
	c) Liabilities for Expenses	13	30,34,874	17,42,507
	d) Liabilities for Other Finance	14	8,34,65,296	4,33,61,716
			45,88,80,963	39,30,51,736
	<u>Net Current Assets</u>		(33,76,90,219)	(28,11,86,207)
2.4	<u>Profit &amp; Loss A/C- Loss carried forward</u>		20,90,01,604	11,58,55,205
2.5	<u>Miscellaneous Expenditure to the Extent Not written off or adjusted.</u>	15	46,59,546	55,91,455
2.6	<u>Contingent Liabilities</u>	16	---	---
			=====	=====
			20,77,54,189	20,77,54,189
			=====	=====

AUDITORS' REPORT TO THE SHAREHOLDERS  
See report annexed

Md. Obaidul Karim  
Managing Director

Golam Mohiuddin  
Director

The annexed schedules from a part of this  
Balance Sheet. LA

Md. Kayes Mahmud  
Company Secretary



# ORION INFUSION LIMITED


## PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 30 JUNE 1999


PARTICULARS	SCHEDULE	1999 Taka	1998 Taka
Sales	17	2,15,99,011	1,38,33,095
Less : Cost Of Goods Sold	18	2,64,55,269	2,49,68,576
Gross Loss		(48,56,258)	(1,11,35,481)
Operating Expenses:			
General and Administrative Expenses	19	1,15,14,231	1,50,83,903
Selling and Distribution Expenses	20	1,37,36,465	1,09,85,878
		2,52,50,696	2,60,69,781
Operating Loss		(3,01,06,954)	(3,72,05,262)
Financial Expenses	21	5,81,02,010	4,66,38,646
Net Loss		(8,82,08,964)	(8,38,43,908)
Loss brought forward		(11,58,55,205)	(3,20,11,297)
Prior Year's Adjustment	22	(49,37,435)	---
Loss Carried forward		(20,90,01,604)	(11,58,55,205)
(Earning) per Share		(43.33)	(41.55)

AUDITORS' REPORT TO THE SHAREHOLDERS  
See report annexed.

The annexed schedules from a part  
of this Profit and Loss Account.



  
Md. Obaidul Karim  
Managing Director

  
Golam Mohiuddin  
Director

  
Md. Kayes Mahmud  
Company Secretary

# ORION INFUSION LIMITED


## CASH FLOWS STATEMENT FOR THE YEAR ENDED 30 JUNE 1999


<u>PARTICULARS</u>	1999 <u>Taka</u>	1998 <u>Taka</u>
Cash & Bank Balance at the Beginning of the year	6,98,425	22,38,039
Cash Flows from Operating Activities :		
Cash Received from Customers	1,90,96,148	95,66,398
Cash Paid to Suppliers & Employees	(4,33,45,474)	(4,26,03,792)
Cash Flows from Operation	(2,42,49,326)	(3,30,37,394)
Income Tax Deducted at Source	(52,307)	(6,375)
Interest Charged	(2,21,16,533)	(4,66,38,646)
	(4,64,18,166)	(7,96,82,415)
Cash Flows from Investing Activities :		
Acquisition of Fixed Assets	(3,67,185)	(6,45,738)
Investments Refunded	2,51,45,871	2,97,05,030
	2,47,78,686	2,90,59,292
Cash Flows from Financing Activities :		
Bank Loans Created	2,39,01,071	4,78,91,345
Issue of Right Shares to General Public	--	35,97,600
Receipt from/ (Payment to) Associated Companies	(15,64,433)	38,32,784
Dividend Paid	(8,19,332)	(62,38,220)
	2,15,17,306	4,90,83,509
Cash & Bank Balances at the Closing of the year	5,76,251 =====	6,98,425 =====


AUDITORS' REPORT TO THE SHAREHOLDERS  
See report annexed.

The annexed schedules from a part  
of this Cash Flow Statement. **LAC**



  
Md. Obaidul Karim  
Managing Director

  
Golam Mohiuddin  
Director

  
Md. Kayes Mahmud  
Company Secretary

SCHEDULES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 1999  
FORMING INTEGRAL PART OF THE FINANCIAL STATEMENTS

SCHEDULE-1

NOTES-GENERAL

(a) Disclosure on Orion Infusion Limited:

This is a public limited company incorporated in Bangladesh on 5 May 1983 and is now under the entrepreneurship of Orion Group. The other shareholders are general public including financial institutions and foreign investors.

The shares of the Company are listed both with the Dhaka and Chittagong Stock Exchanges of Bangladesh. The trading of the shares are however suspended at the stock exchanges.

The Company owns an intravenous (I.V) fluid project for producing life saving injectables, namely intravenous(I.V) fluids and other allied products.

(b) Components of the Financial Statements:

- (i) Balance Sheet as on 30 June 1999;
- (ii) Profit and Loss Account for the year ended 30 June 1999;
- (iii) Cash Flows Statement for the year ended 30 June 1999;
- (iv) Accounting policies and explanatory notes.

(c) Reporting Currency and Level of Precision:

The figures in the financial statements represent Bangladesh Taka, which have been rounded off to the nearest taka except where indicated otherwise.

(d) Tax Holiday:

The Company is enjoying tax-holiday upto 28 February 2000.

(e) Comparative Information:

Comparative information have been disclosed in respect of the year ended 30 June 1997 for all numerical information in the financial statements and also the narrative and descriptive information where it is relevant to an understanding of the current period's financial statements.

Figures of the year ended 30 June 1998 have been reclassified wherever considered necessary to ensure comparability with the current period.





(f) **Compliance with Local Laws:**

The financial statements have been prepared in compliance with the requirements of the Companies Act, 1994; Securities and Exchange Ordinance, 1969; Securities and Exchanges Rules, 1987; Listing Regulations of Dhaka and Chittagong Stock Exchange, and other relevant local laws as applicable. The cash flow from operating activities are computed under direct method as prescribed by the Securities and Exchange Rules, 1987.

(g) Compliance with International Accounting Standards:

The financial statements have been prepared in compliance with the requirements of the International Accounting Standards (IASs) approved by the International Accounting Standards Committee (IASC) and as adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) as applicable.

(h) Reporting Period:

The financial statements of the Company cover one year from 1 July to 30 June next consistently. 1AC





## SCHEDULE-2

### STATEMENTS OF ACCOUNTING POLICIES APPLIED AND EXPLANATORY NOTES:

(i) **Accrual Basis of Accounting:**

The financial statements have been prepared, except for cash flow information, under the accrual basis of accounting.

(ii) **Measurement Basis:**

The financial statements have been prepared using the Historical Cost basis.

(iii) **Tax Holiday Reserve:**

30% of the tax holiday profit has been provided to invest in the same undertaking or in any new industrial undertaking or in stocks and shares of a public company or in government bonds or securities as per Income Tax Law.

(iv) **Fixed Assets:**

Fixed assets are stated at cost less depreciation except land and land development. Net carrying amounts (written down value) are arrived at after deduction of accumulated depreciation from gross carrying amounts (cost).

The gross carrying amounts (cost) represent cost of acquisition or construction, capitalization of pre-production expenditure including interest during construction period.

(v) **Depreciation:**

Depreciation has been charged under straight line method at the following rates:-

<u>Items</u>	<u>Rate Percentage</u>
Freehold building	2½
Leasehold building	4
Plant, machinery and equipment	5
Furniture and fixtures and office equipment	10
Vehicles	20
Books	25

(vi) **Investments:**

Investments are stated at cost.

(vii) **Inventories:**

Inventories have been valued at weighted average cost except finished products stated at trade price without VAT.

(viii) **Workers' participation/ welfare funds:**

Contribution to workers' participation/ welfare funds has been incorporated at 5% of the net profit before such contribution. **LAC**



(ix) **Miscellaneous Expenditure:**

Share issue costs and Pre-operating expenses are stated at cost less amortization at 10% per annum w.e.f. 1 July 1994.

(x) **Sales:**

Turnover comprises the invoice value of goods supplied by the company and represents local sales less 15% VAT.

(xi) **Revenue Recognition:**

Sales is recognized at the time of delivery from godown.

(xii) **Cash and Cash Equivalents:**

Cash in hand and cash at banks have been considered as the cash and cash equivalents for the preparation of these financial statements which were held and available for use by the Company without any restriction and there was insignificant risk of changes in value of these current assets.

(xiii) **Earnings per share (EPS):**

The Company calculates Earnings per Share (EPS) in accordance with the International Accounting Standard (IAS)-33 "Earnings per Share" as adopted in Bangladesh.

**Earnings Basic:**

This represents the earnings for the year attributable to ordinary shareholders. As there was no preference dividend, minority interests and extraordinary items, the net profit after tax has been considered as fully attributable to the ordinary shareholders.

**Weighted Average Number of Ordinary shares Outstanding during the Year:**

This represents the number of ordinary shares outstanding during the beginning of the year plus the number of ordinary shares, if any, issued during the year multiplied by a time weighting factor.

**Earnings per Share (EPS) Basis:**

This has been calculated by dividing the earnings basic by the weighted average number of ordinary shares outstanding during the year. **LAC**



### SCHEDULE - 3 SHARE CAPITAL

	1999 <u>TAKA</u>	1998 <u>TAKA</u>
3.1 <u>Authorised</u>		
1,00,00,000 Ordinary Shares of Tk. 100 each.	100,00,00,000 =====	100,00,00,000 =====
3.2 <u>Issued, subscribed and paid - up</u>		
20,35,976 Ordinary Shares of Tk. 100 each.	20,35,97,600 =====	20,35,97,600 =====
Return of Allotment has not been submitted against allotment of 35,976 right shares.		

3.3 The shareholding pattern is as below :

<u>Description</u>	<u>No. of shareholders</u>	<u>No. of shares held</u>	1999 <u>Holding(%)</u>	1998 <u>Holding(%)</u>
Less then 500 shares	8762	5,41,816	26.61%	27.20%
501 to 5000 shares	292	2,38,360	11.71%	13.08%
5001 to 10000 shares	19	1,29,280	6.35%	3.33%
10001 to 20000 shares	9	77,520	3.81%	7.95%
20001 to above	7	10,49,000	51.52%	48.00%
	-----	-----	-----	-----
Total	9,089	20,35,976	100%	100%
	=====	=====	=====	=====

3.4 The position of Shareholders as on 30 June, 1999 is as follows.

	<u>Nos. of Shareholders</u>	<u>Number of Shares</u>	1999 <u>% of shareholding</u>	1998 <u>% of Shareholding</u>
Sponsors	7	9,42,400	46.29%	46.29%
Foreign Investors	7	59,240	2.91%	2.91%
Financial Institutions	4	1,02,080	5.01%	5.01%
General Public	<u>9,071</u>	<u>9,32,256</u>	<u>45.79%</u>	<u>45.79%</u>
	<u>9,089</u>	<u>20,35,976</u>	<u>100%</u>	<u>100%</u>

### SCHEDULE - 4 RESERVES AND SURPLUS

	1999 <u>TAKA</u>	1998 <u>TAKA</u>
Tax holiday reserve	41,56,589	41,56,589
	-----	-----
	41,56,589 =====	41,56,589 =====





## SCHEDULE - 5

### SCHEDULE OF FIXED ASSETS AS AT 30TH JUNE, 1999

SL No.	Items	Cost		Depreciation				Written Down Value at 30 June 1999 Taka
		On 1 July 1998 Taka	Addition during This year Taka	At 30 June 1999 Taka	Rate (%)	On 1 July 1998 Taka	During this year Taka	At 30 June 1999 Taka
1.	Land & Land Development	94,67,829	---	94,67,829	---	---	---	---
2.	Freehold Building	5,07,95,687	---	5,07,95,687	2.5	62,70,674	12,69,892	75,40,566
3.	Leasehold Building	3,60,42,466	---	3,60,42,466	4	48,18,647	14,41,699	62,60,346
4.	Plant, Machinery & Equipment.	14,37,76,043	2,31,540	14,40,07,583	5	3,28,01,861	72,00,379	4,00,02,240
5.	Furniture and Fixtures	36,96,168	32,220	37,28,388	10	12,87,524	3,71,227	16,58,751
6.	Office Equipment	6,65,228	1,03,425	7,68,653	10	2,02,861	71,694	2,74,555
7.	Vehicles	28,69,140	---	28,69,140	20	20,08,398	5,73,828	25,82,226
8.	Books	12,292	---	12,292	25	9,219	3,073	12,292
	<b>Total Taka</b>	<b>24,73,24,853</b>	<b>3,67,185</b>	<b>24,76,92,038</b>		<b>4,73,99,184</b>	<b>1,09,31,792</b>	<b>5,83,30,976</b>
	<b>1998 Total Taka</b>	<b>24,66,79,115</b>	<b>6,45,738</b>	<b>24,73,24,853</b>		<b>3,64,85,751</b>	<b>1,09,13,433</b>	<b>4,73,99,184</b>
								<b>19,99,25,669</b>

5.1 DEPRECIATION HAS BEEN CHARGED DURING THE YEAR AS UNDER :

1999	
Taka	
84,70,271	
24,61,521	
1,09,31,792	

Cost of Goods Sold ( Schedule 18)  
General & Administrative Expenses ( Schedule 19)

1998	
Taka	
84,58,694	
24,54,739	
1,09,13,433	





## SCHEDULE - 6 INVESTMENT

	1999 <u>TAKA</u>	1998 <u>TAKA</u>
Orioplast Ltd.	2,89,20,739	5,28,72,217
Orion Mushroom Ltd.	11,35,01,457	11,46,95,850
	----- 14,24,22,196 =====	----- 16,75,68,067 =====

These investments are made in the Associated Companies, and are considered good by the directors.

## SCHEDULE - 7 INVENTORIES

	1999 <u>TAKA</u>	1998 <u>TAKA</u>
Raw Materials (Note- 7.1)	5,12,89,016	5,14,73,328
Packing Materials (Note- 7.2)	1,68,83,774	1,51,68,232
Work-in-Process (Note- 7.3)	17,22,930	3,69,525
Finished Products (Note-7.4)	44,26,723	27,71,980
Promotional Materials	3,75,674	9,16,102
Spares & Accessories	5,82,520	6,24,520
Stationery	3,88,934	6,95,588
	----- 7,56,69,571 =====	----- 7,20,19,275 =====

Inventories worth Tk 6,60,18,569 (1998: Tk 6,43,90,234) are lying in various godowns of the Banks which are not released to the Company for its utilization. LA



7.1 Raw Materials

	1999		1998	
	Quantity (Kg)	Taka	Quantity (Kg)	Taka
Dextrose Eanhydrose	6,600	2,76,622	10,544	4,31,477
Potassium Chloride	58	7,450	196	18,098
Sodium Acetate	1,083	1,19,679	726	80,907
Sodium Chloride	2,101	1,04,519	2,837	1,27,983
Metronidazole B.P.	21.48	13,755	5.91	3,841
Cipro Floxazine Lactate	24.47	84,280	7	34,903
Calcium Chloride	34.83	9,495	21.55	7,453
Sodium Lactate	12.226	2,926	268	98,376
Genthamycin	550	58,71,250	550	58,71,250
Thacetazone B.P.	950	56,52,500	950	56,52,500
Chaphalexin Mono Compacted	400	37,80,000	400	37,80,000
Helozone N.F.	1,100	1,37,50,000	1,100	1,37,50,000
Doxyclyne Mono Compacted	225	21,37,500	225	21,37,500
Sulphamethozalone	3,600	85,50,000	3,600	85,50,000
Thiamin H.C.L.	240	6,17,040	240	6,17,040
Metronidazole B.P.	1,000	11,26,000	1,000	11,26,000
Benzoate Metronidazole	650	7,76,100	650	7,76,100
Tetracycline H.C.L.	850	51,85,000	850	51,85,000
Chaphalaxine Mono Compacted	350	32,24,900	350	32,24,900
		5,12,89,016		5,14,73,328



7.2	<u>Packing Materials</u>	1999		1998	
		<u>Quantity</u>	<u>Taka</u>	<u>Quantity</u>	<u>Taka</u>
	PVC Bag 100 ml.	2,28,135 pcs	15,81,052	3,13,105 pcs	20,53,444
	PVC Bag 500 ml.	1,11,486 pcs	12,02,357	1,32,693 pcs	14,31,380
	PVC Bag 1000 ml.	3,12,490 pcs	31,34,528	3,15,277 pcs	31,91,650
	Outer Bag	2,13,000 pcs	1,17,748	2,11,165 pcs	1,06,239
	Stopper	8,30,259 pcs	24,96,428	6,34,801 pcs	17,38,865
	Layflat Tube	29,630kg	55,72,560	22,900kg	43,61,000
	Pyrogen free Medical Tube	2,406kg	5,44,588	2,150kg	3,49,800
	Color roll for I.V. Fluid	630roll	9,20,254	396roll	5,94,000
	Outer Label	44,982pcs	18,759	36,438pcs	16,217
	Infusion Set	273ctn	10,65,325	292ctn	11,37,325
	Cartoon	708pcs	18,808	811pcs	26,132
	Others	-----	2,11,367	-----	1,62,180
			=====		=====
			1,68,83,774		1,51,68,232
			=====		=====




	1999		1998	
	<u>Quantity</u>	<u>Taka</u>	<u>Quantity</u>	<u>Taka</u>
Dextropac 500 ml.	-----	-----	1,344	56,448
Dextropac 1000 ml.	1,347	76,348	1,139	62,808
Dextrosal 500ml.	2,326	97,692	1,047	43,994
Dextrosal 1000 ml.	6,927	3,97,610	1,017	58,368
Dextropac 10 - 500 ml.	2,363	1,08,698	695	31,970
Dextropac 10 - 1000 ml.	2,756	1,57,092	764	43,548
Dextrosal Baby	2,295	87,210	----	----
Hartman 1000 ml.	4,131	1,89,282	1,590	72,389
Salpac 1000 ml	1,279	54,997	-----	-----
Maprocin 100 ml	4,677	3,92,728	-----	-----
Nidazyl 100 ml	4,695	1,61,273	-----	-----
		<u>17,22,930</u>		<u>3,69,525</u>
		=====		=====





Finished Products

	1999		1998	
	<u>Quantity</u>	<u>Taka</u>	<u>Quantity</u>	<u>Taka</u>
Dextropac 500 ml.	7,270	3,05,340	4,974	2,08,908
Dextropac 1000 ml.	7,580	4,29,634	4,594	2,60,400
Dextrosal 500ml.	5,137	2,15,754	5,813	2,44,159
Dextrosal 1000 ml.	6,209	3,56,397	2,743	1,57,457
Dextropac 10 - 500 ml.	5,670	2,60,820	4,164	1,91,544
Dextropac 10 - 1000 ml.	6,913	3,94,041	2,634	1,50,138
Dextrosal Baby	2,278	86,564	2,969	1,12,822
Dextrosal Mini	3,616	1,51,872	3,702	1,55,484
Hartman 500 ml.	8,199	3,25,582	1,099	43,627
Hartman 1000 ml.	2,895	1,32,649	1,806	82,791
Dianak 500 ml.	7,431	2,82,378	4,095	1,55,609
Dianak 1000 ml.	5,439	2,71,950	2,448	1,22,378
Nidazyl 100 ml.	3,336	1,14,592	3,092	1,06,212
Salpac 500 ml.	3,444	1,13,652	4,909	1,61,997
Salpac 1000 ml.	1,639	70,477	1,618	69,574
Maprocin 100ml	10,897	9,15,021	9,148	5,48,880
		44,26,723		27,71,980
		=====		=====



SCHEDULE - 8  
SUNDRY DEBTORS

1999		1998	
<u>Nos</u>	<u>TAKA</u>	<u>Nos</u>	<u>TAKA</u>
Pharmacies 2,194	1,11,51,634	Pharmacies 921	91,16,546
Hospitals 74	18,64,270	Hospitals 46	14,08,994
Clinics 305	10,26,075	Clinics 152	10,13,576
-----	-----	-----	-----
2,573	1,40,41,979	1,119	1,15,39,116
===	=====	===	=====

These are unsecured but considered good by the directors.

SCHEDULE - 9  
DEPOSITS AND OTHERS RECEIVABLE

	1999	1998
<u>Advances:</u>	<u>TAKA</u>	<u>TAKA</u>
Advance Income Tax	10,77,287	10,24,980
Tour Advance	71,007	59,375
Security Service Advance	9,200	9,200
	11,57,494	10,93,555
<u>Deposits:</u>		
VAT Deposit	1,85,826	1,49,649
Lease Deposit	25,94,080	25,94,080
Security Deposits	14,74,173	14,53,573
Earnest Money	2,51,571	3,26,571
Protirakhya Sanchyapatra	1,00,000	1,00,000
L/C Margin Deposit	19,30,074	2,45,993
	65,35,724	48,69,866
Due from Orion Laboratories Ltd. (an Associated Company)	2,32,09,725	2,16,45,292
	-----	-----
	3,09,02,943	2,76,08,713
	=====	=====

The receivables are unsecured but considered good by the directors. **LAC**



SCHEDULE - 10

CASH AND BANK BALANCES


	1999 <u>TAKA</u>	1998 <u>TAKA</u>
Agrani Bank, A/c No. 1006, WASA Branch	2,11,654	4,66,589
Agrani Bank, A/c No. 9933-3, WASA Branch	2,720	2,720
Agrani Bank, A/c No. 668, WASA Branch	11,406	864
Janata Bank, Corporate Branch	2,098	2,098
Pubali Bank Ltd, Tejgaon Branch.	24,126	40,583
Bangladesh Shilpa Bank, Dhaka	65	65
Dhaka Bank Ltd, Banani Branch	14,466	14,466
National Bank Ltd, Imamgonj Branch	580	580
National Bank Ltd, Mohakhali Branch	2,10,661	70,992
Rupali Bank Ltd, T.C.B Branch	<u>5,604</u>	<u>--</u>
	483,380	598,957
Cash in Hand	92,871	99,468
	----- 5,76,251 =====	----- 6,98,425 =====

SCHEDULE - 11

BANK LOANS

	1999 <u>TAKA</u>	1998 <u>TAKA</u>
<u>Cash Credits:</u>		
Agrani Bank, C.C. (P) - 5, WASA Branch	31,60,565	38,45,010
Agrani Bank, C.C. (H) - 14, WASA Branch	<u>29,23,05,762</u>	<u>27,04,55,334</u>
	29,54,66,327	27,43,300,344
Janata Bank, C.C. (P) - 12, Corporate Branch	<u>6,05,08,796</u>	<u>6,05,08,796</u>
	35,59,75,123	33,48,09,140
<u>LIM:</u>		
Agrani Bank, WASA Branch	<u>83,07,220</u>	<u>84,20,354</u>
Rupali Bank Ltd, T.C.B Branch	<u>28,48,222</u>	<u>-----</u>
	1,11,55,422	84,20,354
	----- 36,71,30,565 =====	----- 34,32,29,494 =====

The tenure of the facilities from Agrani Bank and Janata Bank have expired but the banks have not reviewed the facilities. The Company has filed suits against Agrani Bank for non-renewal of the facilities, with the Session Court which are still pending for verdict. Janata Bank has filed suit against the Company, with the Loan Recovery Court, which is contested by the Company.



SCHEDULE - 12

LIABILITIES FOR GOODS SUPPLIED

<u>Supplier</u>	1999 (TAKA)	1998 (TAKA)
Adfame	750	-----
Fahad Enterprise	1,86,857	67,867
Pioneer Scientific Stores	-----	28,429
Mokbul Ahmed	178	-----
Nazmu Electric Co.	5,611	2,129
Shapla Enterprise	-----	4,27,463
Superior Plastic Ind.	50,732	40,354
Slect	2,43,713	2,61,713
Inter Plag Trading	76,837	96,613
Core Health Care Ltd.	4,26,763	9,48,974
Surma Traders	23,000	23,000
Sazan Enterprise	6,076	-----
Trade International	-----	57,800
Poly Chems.	8,605	6,755
Pigment	2,13,608	3,38,607
St. Martin Commodities	-----	16,100
Royal Printing	3,532	3,532
Firoz Traders	9,51,277	8,58,497
Elit Computer Service	21,000	98,000
Sundarban Courier Service	13,772	-----
Toshfa Enterprise	23,490	24,185
Popular Advertising	5,203	13,685
Bangladesh Accessory	2,99,505	2,61,426
Prism	-----	2,91,348
Reliance Enterprise	14,18,140	4,25,129
A.B. Traders	-----	48,500
Khan & Deen Traders	18,000	-----
Shahid Enterprise	47,119	-----
Hope Pacaging Ltd.	1,860	1,860
City Chemical Ltd.	18,653	-----
Ledger Printers	3,25,759	1,00,810
Sabina :eather	7,200	-----
Tripti Industries Ltd.	25,000	-----
Anna Sha Packaging	3,000	-----
Unique Trade Syndicate	2,27,188	-----
New Look	28,800	-----
Gias Enterprise	22,600	-----
Thoin Chemical	15,000	-----
Kumu Pens	38,400	-----
Uma Export	4,40,000	-----
Sim Bangladesh Ltd.	14,500	-----
RM Systems Ltd.	24,750	-----
Creative Engineering ltd.	13,750	-----
Others	-----	2,75,243
	-----	-----
	52,50,228	47,18,019
	=====	=====

These are unsecured. LAL





**SCHEDULE- 13**  
**LIABILITIES FOR EXPENSES**

	1999 <u>TAKA</u>	1998 <u>TAKA</u>
Gas and Electricity	3,21,248	2,24,166
Salaries, Wages and Allowances	25,63,626	14,18,341
Audit Fee	1,50,000	1,00,000
	-----	-----
	<u>30,34,874</u>	<u>17,42,507</u>
	=====	=====

**SCHEDULE - 14**  
**LIABILITIES FOR OTHER FINANCE**

	1999 <u>TAKA</u>	1998 <u>TAKA</u>
Workers' Participation/Welfare Funds	26,67,776	26,67,776
Dividends Payable	3,98,74,608	4,06,93,940
Provision for Interest on Bank Loans	4,09,22,912	-----
	-----	-----
	<u>8,34,65,296</u>	<u>4,33,61,716</u>
	=====	=====

The Company could not pay the dividends within statutory time limit of 60 days as the banks did not renew the banking facilities, forcing the Company to slow down production and to default payments.

**SCHEDULE - 15**  
**MISCELLANEOUS EXPENDITURE**

	1999 <u>TAKA</u>	1998 <u>TAKA</u>
Share Issue Expenses	39,20,607	47,04,728
Pre-operating Expenses	7,38,939	8,86,727
	-----	-----
	<u>46,59,546</u>	<u>55,91,455</u>
	=====	=====
<b>15.1 <u>Share Issue Expenses</u></b>		
Opening Balance	47,04,728	54,88,849
Less Written of at 10%	<u>7,84,121</u>	<u>7,84,121</u>
Closing Balance:	<u>39,20,607</u>	<u>47,04,728</u>
	=====	=====
<b>15.2 <u>Pre-operating Expenses</u></b>		
Opening Balance	8,86,727	10,34,515
Less Written of at 10%	<u>1,47,788</u>	<u>1,47,788</u>
Closing Balance	<u>7,38,939</u>	<u>8,86,727</u>
	=====	=====



SCHEDULE -16  
CONTINGENT LIABILITIES

Claim raised by the VAT Authority against the Company for value added tax (VAT) aggregating Tk 3,77,98,752. The Company has filed appeal against such claim to the High Court Division of the Supreme Court of Bangladesh, which is still pending for verdict.

SCHEDULE -17  
SALES REVENUE

	1999		1998	
	<u>Quantity</u>	<u>Taka</u>	<u>Quantity</u>	<u>Taka</u>
Dextropac 500ml	28,229	11,85,618	35,406	14,87,052
Dextropac 1000ml	26,213	14,85,753	22,690	12,51,211
Dextrosal 500ml	27,991	11,75,622	20,500	8,65,663
Dextrosal 1000ml	23,451	13,46,087	18,121	10,40,189
Dextropac-10 -500ml	12,534	5,76,564	16,581	5,47,155
Dextropac -10- 1000ml	23,767	13,54,719	21,987	9,45,441
Dianak 500ml	24,350	9,25,300	32,930	19,75,809
Dianak 1000ml	15,112	7,55,600	19,654	9,04,084
Salpac 500ml	21,379	7,05,507	16,701	9,51,957
Salpac 1000ml	6,916	2,97,388	7,213	2,74,094
Hartman 500ml	22,712	9,01,871	4,198	1,76,316
Hartman 1000ml	23,983	10,98,902	23,988	9,52,257
Dextrosal baby	37,109	14,10,142	14,987	6,87,039
Dextrosal mini	20,918	8,78,556	2,810	85,030
Nidazyl 100ml	1,12,559	38,66,402	1,301	51,513
Maprocin 100ml	60,583	36,34,980	27,631	16,38,285
		-----		-----
		2,15,99,011		1,38,33,095
		=====		=====

SCHEDULE - 18  
COST OF GOODS SOLD

	1999	1998
	<u>TAKA</u>	<u>TAKA</u>
Raw Materials Consumed (Schedule 18.1)	23,32,787	14,38,900
Packing Materials Consumed (Schedule 18.2)	1,17,80,908	72,40,759
Wages, Allowances and Bonus (Schedule 18.3)	31,80,454	29,40,942
Gas	8,89,289	6,58,172
Electricity	6,80,280	7,29,748
Fuel and Lubricant	1,18,859	1,68,940
Research, Test and Analysis Expenses	92,819	1,65,169
Factory Overhead Expenses	19,17,750	17,37,429
Work-in-process Differential (Schedule 18.4)	(13,53,405)	23,59,197
Finished products Inventory Differential (Schedule 18.5)	(16,54,743)	(9,29,374)
Depreciation (Schedule 5.1)	84,70,271	84,58,694
	-----	-----
	2,64,55,269	2,49,68,576
	=====	=====



## SCHEDULE - 18.1

<u>Raw Materials Consumption</u>	<u>1999</u>		<u>1998</u>	
	<u>Quantity</u>	<u>Taka</u>	<u>Quantity</u>	<u>Taka</u>
Dextrose Anhydrous	36.29MT	15,06,001	18.867MT	7,19,200
Potassium Chloride	0.24MT	28,034	0.242MT	22,052
Sodium Acetate	1.239MT	1,31,481	1.267MT	1,20,318
Sodium Chloride	5.236MT	2,55,494	4.551MT	2,10,042
Metronidazole	0.111MT	73,263	0.06257MT	39,019
Ciprofloxazine	0.0325MT	1,21,724	0.017MT	84,515
Calcium Chloride	0.0367MT	10,626	0.03245MT	11,162
Sodium Lactate	0.755MT	2,06,164	0.664MT	2,32,592
TOTAL		=====		=====
		23,32,787		14,38,900
		=====		=====

These are imported. **LAC**



## SCHEDULE - 18.2

<u>Packing Materials Consumption</u>	<u>1999</u>		<u>1998</u>	
	<u>Quantity</u>	<u>Amount</u>	<u>Quantity</u>	<u>Amount</u>
PVC Bag 100 ml.	1,85,114 pcs	13,03,587	75,765 pcs	4,68,228
PVC Bag 500 ml.	2,13,866 pcs	19,28,275	1,41,696 pcs	12,92,000
PVC Bag 1000 ml.	1,48,291 pcs	15,09,252	63,084 pcs	8,81,462
Outer Bag	5,52,793 pcs	3,30,429	3,85,327 pcs	1,92,664
Stopper	5,46,921 pcs	18,13,432	3,00,805 pcs	8,23,974
Layflat Tube	12,036 kg	28,74,939	9,793 kg	18,64,923
Pyrogen free Medical Tube	1,490 kg	2,20,699	3,111 kg	2,02,149
Color roll for I.V. Fluid	289 roll	4,64,375	204roll	2,81,585
Outer Label	21,531 pcs	10,432	1,00,612 pcs	44,269
Infusion Set	19 ctn	72,000	123 ctn	4,78,600
Cartoon	29,082 pcs	9,45,165	20,915 pcs	6,82,725
Others	---	3,08,323	---	28,182
		<u>1,17,80,908</u>		<u>72,40,759</u>

	<u>1999</u>		<u>1998</u>	
	<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>
Imported	54,45,445	46	58,14,319	80
Local	63,35,463	54	14,26,440	20
	<u>1,17,80,908</u>	<u>100</u>	<u>72,40,759</u>	<u>100</u>





18.3 The break-up of Wages, Allowances and Bonus is on below:	1999		1998	
	<u>Number</u>	<u>Taka</u>	<u>Number</u>	<u>Taka</u>
Employees drawing Tk 3,000 per month or above	10	8,17,745	11	9,70,604
Employees drawing less than Tk 3,000 per month	<u>96</u>	<u>23,62,709</u>	<u>82</u>	<u>19,70,338</u>
	<u>106</u>	<u>31,80,454</u>	<u>94</u>	<u>29,40,942</u>

1999	1998
<u>Taka</u>	<u>Taka</u>

#### 18.4 WORK-IN-PROCESS DIFFERENTIALS

Opening Stock	3,69,525	27,28,722
Less : Closing Stock	17,22,930	3,69,525
	=====	=====
Work-in process differential	(13,53,405)	23,59,197
	=====	=====

#### 18.5 FINISHED PRODUCTS DIFFERENTIALS

Opening Stock	27,71,980	18,42,606
Less : Closing Stock	<u>44,26,723</u>	<u>27,71,980</u>
Finished Products differential	(16,54,743)	(9,29,374)
	=====	=====



SCHEDULE - 19  
ADMINISTRATIVE AND GENERAL EXPENSES

	1999 <u>Taka</u>	1998 <u>Taka</u>
Salaries, Allowances and Bonus	15,23,316	20,69,060
Director's Remuneration & Allowances	3,98,000	3,98,000
Postage, Telephone and Telegram	1,65,617	1,85,073
Printing and Stationery	42,285	51,017
Repairs and Maintenance	86,992	1,69,783
Share Issue Expenses written off (Schedule 15.1)	1,47,788	1,47,788
Pre-Operating Expenses written off (Schedule 15.2)	7,84,121	7,84,121
Advertisement and publication	22,883	1,05,697
Travelling and Conveyance	1,48,515	1,11,850
Security & Guard Expenses	1,35,600	1,28,054
Bank Charges & Commission	2,21,616	1,19,743
News Papers and Periodicals	2,164	1,842
Legal & Professional Exp.	2,23,630	52,040
Entertainment	18,279	38,813
Audit Fee	50,000	50,000
Rent, Rates and Taxes	20,072	27,713
Lease Rent	41,22,455	76,55,345
Sundry Expenses	4,23,102	3,74,863
Insurance	5,02,709	1,58,362
Depreciation (Schedule 5.1)	24,61,521	24,54,739
	----- 1,15,14,231 =====	----- 1,50,83,903 =====

Other than audit fee, no fee was paid to the auditors.  
The break-up of Salaries, Allowances and Bonus is as below:

	<u>1999</u>		<u>1998</u>	
	<u>Number</u>	<u>Taka</u>	<u>Number</u>	<u>Taka</u>
Employees drawing Tk 3000 per month or above	20	13,81,554	24	19,24,136
Employees drawing less than Tk 3000 per month	<u>6</u>	<u>1,41,762</u>	<u>6</u>	<u>1,44,924</u>
	<u>26</u>	<u>15,23,316</u>	<u>30</u>	<u>20,69,060</u>



**SCHEDULE - 20**  
**SELLING AND DISTRIBUTION EXPENSES**

	1999 <u>Taka</u>	1998 <u>Taka</u>
Salaries, Allowances and Bonus	6,19,424	9,85,800
Carrying and Delivery Expenses	20,46,279	12,04,526
Sales Force Expenses	97,16,455	78,81,150
Postage, Telephone and Telegram	2,49,650	1,73,064
Cost of Tender Schedule	5,161	8,100
Conference Expenses	88,616	12,899
Other Selling Expenses	10,10,880	7,20,339
	<u>1,37,36,465</u> =====	<u>1,09,85,878</u> =====

The break-up of Salaries, Allowances and Bonus is as below:


	1999	1998
	<u>Number</u> <u>Taka</u>	<u>Number</u> <u>Taka</u>
Employees drawing Tk 3000 per month or above	3      5,67,761	6      9,36,597
Employees drawing less than Tk 3000 per month	<u>2</u> <u>51,663</u>	<u>2</u> <u>49,203</u>
	5      6,19,424	8      9,85,800
	<u>=====</u>	<u>=====</u>

**SCHEDULE - 21**  
**FINANCIAL EXPENSES**

	1999 <u>Taka</u>	1998 <u>Taka</u>
Interest on Cash Credits	5,65,75,266	4,42,98,967
Interest on LIM	15,26,744	23,39,679
	<u>5,81,02,010</u> =====	<u>4,66,38,646</u> =====

**SCHEDULE - 22**  
**PRIOR YEAR'S ADJUSTMENT**

	1999 <u>Taka</u>	1998 <u>Taka</u>
Interest on Cash Credits (Janata Bank, C.C.-12) not provided for the period from 1 January to 30 June 1998, now provided	49,37,435	----
	<u>49,37,435</u> =====	<u>-----</u> =====



## SCHEDULE-23

### GENERAL

23.1 The capacity and actual production of the Company for the year are as below:

Item	Capacity	Actual Production	Percentage	Reasons for under-capacity utilization.
Intravenous fluid and Injectables	42,00,000	5,41,202	12.89%	Lack of working capital forcing slow down of activity

23.2 There was no capital expenditure contracted but not incurred or provided for; or authorised by the Board of Directors of the Company but not contracted, at balance sheet date.

23.3 There was no claim against the Company not acknowledged as debt or no contingent liability other than those disclosed in Schedule-16 or provided for, on balance sheet date.

23.4 There was no credit facilities available to the Company but not availed of other than those disclosed in Schedule-11.


23.5 No compensation was allowed to the Managing Director, no fee was paid to any directors or no amount was paid to any directors for any special services other than those disclosed in Schedule-19.


23.6 No amount is due to or from any director or Associated Company other than those disclosed in Schedules-6 and 9.


23.7 No commission, brokerage or discount was paid against sales other than that in the ordinary course of business.

23.8 There was neither any earning in foreign exchange against sales or services, nor any disbursement in foreign exchange for royalty or services.

23.9 The company had 7 foreign shareholders having 59,240(1998:59,340) shares on 30 June 1999. No dividend was remitted to foreign shareholders during the year. LAL

  
Md. Obaidul Karim  
Managing Director

  
Golam Mohiuddin  
Director

  
Md. Kayes Mahmud  
Company Secretary